Table 2.
Demographics and characteristics of the interviewed patients
| Age, years | |
|---|---|
| Mean (range) | 52 (41–65) |
| Age at HAE diagnosis, years | |
| Mean (range) | 30.5 (19–40) |
| Time from diagnosis to discuss LTP with HCP, years | |
| Mean (range) | 15.5 (11–24) |
| LTP status, n (%) | |
| LTP naïve | 4 (50) |
| Currently taking LTPa | 4 (50) |
| Attacks experienced in the last 12 months, n (%) | |
| One | 5 (62.5) |
| Twob | 2 (25) |
| Three | 1 (12.5) |
HAE, hereditary angioedema; HCP, healthcare professional; LTP, long-term prophylaxis
an = 2, androgen-receiving patients who were initiated on LTP before HAE-targeted LTP was available to them; n = 2, HAE-targeted LTP
bOne patient reported 1–2 attacks per year